A retrospective study assessing the response of low-dose ipilimumab and anti-PD1 combination in in patients with advanced melanoma in the real-world
Latest Information Update: 16 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress